221 related articles for article (PubMed ID: 25399517)
1. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.
Yan L; Da Silva DM; Verma B; Gray A; Brand HE; Skeate JG; Porras TB; Kanodia S; Kast WM
Prostate; 2015 Feb; 75(3):280-91. PubMed ID: 25399517
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
4. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
5. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
6. Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model.
Simons BW; Cannella F; Rowley DT; Viscidi RP
Cancer Immunol Immunother; 2020 Apr; 69(4):641-651. PubMed ID: 32016503
[TBL] [Abstract][Full Text] [Related]
7. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
9. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression.
Kanodia S; Da Silva DM; Karamanukyan T; Bogaert L; Fu YX; Kast WM
Cancer Res; 2010 May; 70(10):3955-64. PubMed ID: 20460520
[TBL] [Abstract][Full Text] [Related]
10. Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
Karan D
Vaccine; 2017 Oct; 35(43):5794-5798. PubMed ID: 28939158
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Stringhini M; Mock J; Fontana V; Murer P; Neri D
MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
[TBL] [Abstract][Full Text] [Related]
13. Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer.
Mo L; Chen Q; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
Vaccine; 2017 Oct; 35(43):5932-5938. PubMed ID: 28923424
[TBL] [Abstract][Full Text] [Related]
14. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
15. Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition.
Wang Y; Zhu M; Yu P; Fu YX
J Immunol; 2010 Feb; 184(3):1589-95. PubMed ID: 20042587
[TBL] [Abstract][Full Text] [Related]
16. Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches.
Horn T; Grab J; Schusdziarra J; Schmid S; Maurer T; Nawroth R; Wolf P; Pritsch M; Gschwend JE; Kübler HR; Beckhove P
Int J Cancer; 2013 Nov; 133(9):2145-56. PubMed ID: 23625723
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
18. Human prostate stem cell antigen and HSP70 fusion protein vaccine inhibits prostate stem cell antigen-expressing tumor growth in mice.
Dong L; Zhang X; Ren J; Wu S; Yu T; Hou L; Fu L; Yi S; Yu C
Cancer Biother Radiopharm; 2013 Jun; 28(5):391-7. PubMed ID: 23701419
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice.
Xiao L; Joo KI; Lim M; Wang P
PLoS One; 2012; 7(11):e48866. PubMed ID: 23139820
[TBL] [Abstract][Full Text] [Related]
20. A GMCSF-Neuroantigen Tolerogenic Vaccine Elicits Systemic Lymphocytosis of CD4
Moorman CD; Curtis AD; Bastian AG; Elliott SE; Mannie MD
Front Immunol; 2018; 9():3119. PubMed ID: 30687323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]